Clinical Trials on Hematologic Diseases in Germany

Total 21722 results

Omeros Corporation

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Thrombotic Microangiopathies | Hematopoietic Stem Cell Transplantation

United States, Germany, Israel, Netherlands, Spain
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Cinnagen

Completed

Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

Anemia in End-Stage Renal Disease

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

Spain, Germany, Malaysia, Latvia
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany
Heinrich-Heine University, Duesseldorf
Celgene Corporation; Koordinierungszentrum für Klinische Studien Düsseldorf

Active, not recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Chronic Myelomonocytic Leukemia | IDH2 Gene Mutation | IDH2 R172 | IDH2 R140

Germany
Novartis Pharmaceuticals

Completed

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Germany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Octapharma

Not yet recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Hemophilia A

Spain, France, Finland, Germany, Italy, Serbia
GWT-TUD GmbH

Active, not recruiting

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

Germany
Cancer Trials Ireland

Completed

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States, Ireland, Israel, Germany
Novartis Pharmaceuticals

Completed

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (PAVE)

Polycythemia Vera

Germany
Bioverativ, a Sanofi company

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Purpura, Thrombocytopenic, Idiopathic

United Kingdom, United States, Germany
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Myelo Therapeutics GmbH

Completed

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (MyeloConcept)

Breast Cancer | Myelosuppression | Chemotherapy-Induced Neutropenia

Germany
Biotest
PRA Health Sciences

Completed

Adjusted Fibrinogen Replacement Strategy (AdFIrst)

Bleeding Disorder | Hypofibrinogenemia; Acquired

Belgium, Czechia, Germany, Poland, Spain, Switzerland, United Kingdom
Incyte Corporation

Completed

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Polycythemia Vera

United States, Belgium, Germany, Spain, Italy, United Kingdom, Ireland
RWTH Aachen University
Novartis Pharmaceuticals

Active, not recruiting

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Germany
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Anemia

France, United Kingdom, Germany, Spain, Belgium, Italy
Octapharma

Completed

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Severe Hemophilia A

Germany, Austria, United Kingdom, Bulgaria
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Beta-Thalassemia

France, United Kingdom, United States, Thailand, Italy, Germany
UCSF Benioff Children's Hospital Oakland
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Medical... and other collaborators

Completed

Multi-Center Study of Iron Overload: Pilot Study (MCSIO)

Sickle Cell Disease | Thalassemia | Diamond-Blackfan Anemia

United Kingdom, United States, Germany
Amgen

Terminated

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Myelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AML

United States, Canada, Germany, Netherlands
Anaveon AG

Terminated

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Hematologic Diseases | Multiple Myeloma | Refractory Multiple Myeloma | Adult Disease | Relapsed Cancer

Spain, Germany, France, Denmark, Switzerland
Pfizer

Completed

Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

Non-Interventional Study

Germany
Calypso Biotech BV

Completed

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease | Eosinophilic Esophagitis

Netherlands, Belgium, Finland, Germany, Norway
Pfizer

Completed

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Hemophilia A

Spain, France, Turkey, Netherlands, Germany, Italy, Ukraine
Abbott Medical Devices

Completed

XIENCE 28 Global Study

Coronary Artery Disease | Renal Insufficiency | Anemia | Thrombocytopenia | Coagulation Disorder | Stroke, Ischemic | Stroke Hemorrhagic | Bleeding Disorder | Hematological Disease

China, Spain, Belgium, Germany, Portugal, Switzerland, Hong Kong, United Kingdom, Austria, Italy, Netherlands, Singapore, Taiwan
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen

Completed

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Multiple Myeloma

Austria, Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Recurrent Disease | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase of Disease | Chronic Phase of Disease

United States, Germany, Italy
Novo Nordisk A/S

Completed

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

Spain, Germany, Switzerland, Italy, Israel
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

United States, Germany, United Kingdom, France, Greece, Italy
Octapharma

Active, not recruiting

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Von Willebrand Disease

United States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
University of Ulm

Active, not recruiting

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

Primary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MF

Germany
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis (MERCUR)

Anemia

Germany
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany, Saudi Arabia
Bayer

Completed

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Hemophilia A | Hemophilia B

Ukraine, United Kingdom, Bulgaria, Germany, Japan
Universitätsklinikum Hamburg-Eppendorf

Completed

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Germany
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
BerGenBio ASA

Active, not recruiting

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Germany, Italy, Norway
Novartis Pharmaceuticals

Completed

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Germany, Spain, Singapore
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Willebrand International Non-interventional Global Surveillance

Von Willebrand Disease

Norway, Germany, Italy, Belgium, Czechia, Finland, Greece
Universitätsklinikum Hamburg-Eppendorf

Completed

Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma

Multiple Myeloma

Germany

Clinical Trials on Hematologic Diseases in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations